RIVA-ESOMEPRAZOLE DR CAPSULE (DELAYED RELEASE)
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
16-05-2012
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE)
Inapatikana kutoka:
LABORATOIRE RIVA INC.
ATC kanuni:
A02BC05
INN (Jina la Kimataifa):
ESOMEPRAZOLE
Kipimo:
40MG
Dawa fomu:
CAPSULE (DELAYED RELEASE)
Tungo:
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 40MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
30/90
Dawa ya aina:
Prescription
Eneo la matibabu:
PROTON-PUMP INHIBITORS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0145162002; AHFS:
Idhini hali ya:
CANCELLED PRE MARKET
Idhini ya tarehe:
2016-05-31
Tabia za bidhaa
PRODUCT MONOGRAPH
PR
RIVA-ESOMEPRAZOLE DR
ESOMEPRAZOLE (AS ESOMEPRAZOLE MAGNESIUM DIHYDRATE)
20 MG AND 40 MG DELAYED-RELEASE CAPSULES
H
+
, K
+
-ATPASE INHIBITOR
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville Québec
J7C 3V4
DATE OF PREPARATION:
May 16, 2012
SUBMISSION CONTROL NO: 154931
_ _
_Riva-ESOMEPRAZOLE DR Product Monograph _
_Page 2 of 48_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.......................................................3
SUMMARY PRODUCT
INFORMATION..............................................................................3
INDICATIONS
AND CLINICAL USE
....................................................................................3
CONTRAINDICATIONS.........................................................................................................4
WARNINGS
AND
PRECAUTIONS........................................................................................4
ADVERSE
REACTIONS
.........................................................................................................7
DRUG
INTERACTIONS........................................................................................................14
DOSAGE
AND
ADMINISTRATION....................................................................................16
OVERDOSAGE......................................................................................................................18
ACTION
AND CLINICAL PHARMACOLOGY
..................................................................19
STORAGE
AND
STABILITY................................................................................................22
DOSAGE
FORMS, COMPOSITION AND PACKAGING
...................................................22
PART II: SCIENTIFIC INFORMATION
.............................................................................24
PHARMACEUTICAL
INFORMATION...............................................................................24
CLINICAL
TRIALS..........................................................................
Soma hati kamili
